Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006068 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
A Phase 3 study of Ulcerative Colitis (UC), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 950
- Enrollment target
- 20
- Study locations
NCT03006068 is a Phase 3 study of Ulcerative Colitis (UC) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 950 participants, above the 709-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT03006068, a Phase 3 study of Ulcerative Colitis (UC), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 950 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib (ABT-494)
Study Locations (20)
California
- Citrus Valley Gastroenterology /ID# 151915 - Covina
- Newport Huntington Medical Group /ID# 217006 - Huntington Beach
- UC San Diego Health System /ID# 155187 - La Jolla
- United Medical Doctors /ID# 207467 - Los Alamitos
- TLC Clinical Research Inc /ID# 216830 - Los Angeles
- Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157082 - Los Angeles
- Facey Medical Foundation /ID# 203135 - Mission Hills
- United Medical Doctors - Murrieta /ID# 151213 - Murrieta
- Ventura County Gastroenterology Medical Group /ID# 163417 - Oxnard
- Inland Empire Clinical Trials, LLC /ID# 216163 - Rialto
- San Diego Clinical Trials /ID# 212121 - San Diego
- Medical Assoc Research Grp /ID# 169149 - San Diego
- Univ of California San Francis /ID# 164583 - San Francisco
Arizona
- Delsol Research Management, Ll /Id# 170130 - Chandler
- Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211886 - Mesa
- Duplicate_Arizona Arthritis & Rheumatology Research, PLLC /ID# 169823 - Sun City
- Adobe Clinical Research LLC /ID# 155249 - Tucson
- Duplicate_University of Arizona /ID# 150568 - Tucson
Alabama
- East View Medical Research, LLC /ID# 171184 - Mobile
- CB Flock Research Corporation /ID# 165986 - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006068
The ClinicalTrials.gov registry entry for NCT03006068 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 709-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (34% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03006068 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03006068 about?
NCT03006068 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)". This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substu...
What is the current status of trial NCT03006068?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 950 participants. The study started on 2017-01-31. Estimated completion is 2027-07.
What conditions does trial NCT03006068 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
What interventions are being tested in trial NCT03006068?
The interventions under investigation include: Placebo (DRUG), Upadacitinib (ABT-494) (DRUG).
Who is sponsoring clinical trial NCT03006068?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03006068 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
COMPLETED · Phase 3
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.